6L9 Stock Overview ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
ViewRay, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for ViewRay Historical stock prices Current Share Price US$0.025 52 Week High US$4.60 52 Week Low US$0.0005 Beta 0.76 1 Month Change 0% 3 Month Change 284.62% 1 Year Change -99.39% 3 Year Change -99.04% 5 Year Change -99.68% Change since IPO -99.57%
Recent News & Updates Motion For Case Conversion Approved for ViewRay, Inc. Oct 27
Nasdaq To Delist the Common Stock of ViewRay Sep 08
ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index Jul 27 ViewRay Announces Commencement of Nasdaq Delisting Proceedings Jul 24
ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board Jul 23 Motion for Joint Administration Filed by ViewRay, Inc. See more updates Motion For Case Conversion Approved for ViewRay, Inc. Oct 27
Nasdaq To Delist the Common Stock of ViewRay Sep 08
ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index Jul 27 ViewRay Announces Commencement of Nasdaq Delisting Proceedings Jul 24
ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board Jul 23 Motion for Joint Administration Filed by ViewRay, Inc.
Viewray, Inc. Announces Resignation of Susan Schnabel from Board of Directors Jul 10
ViewRay Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market Jul 03
First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.14 loss in 1Q 2022) May 12
ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023 May 10
Full year 2022 earnings released: US$0.59 loss per share (vs US$0.67 loss in FY 2021) Mar 01
ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 01
ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of Directors Jan 22
ViewRay, Inc. Announces Findings from the Phase III Randomized Controlled Mirage Trial Jan 13
ViewRay, Inc. Announces CFO Changes Jan 10
Insider recently bought €113k worth of stock Nov 30
Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.15 loss in 3Q 2021) Nov 08
ViewRay, Inc. Provides Revenue Guidance for the Full Year 2022 Nov 02
ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial Oct 29
ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial Oct 28
ViewRay, Inc. Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients Oct 25
ViewRay, Inc. Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy Oct 19
ViewRay, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 15
ViewRay Announces China NMPA Approval of its MRIdian(R) MRI-Guided Radiation Therapy for Cancer Patients Sep 08
ViewRay, Inc. Selects Denver for Headquarters Aug 09
Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.19 loss in 2Q 2021) Aug 03
Viewray, Inc. Updates Earnings Guidance for the Year 2022 Aug 03
ViewRay, Inc. to Report Q2, 2022 Results on Aug 02, 2022 Jul 20
President recently bought €379k worth of stock May 13
First quarter 2022 earnings released: US$0.14 loss per share (vs US$0.17 loss in 1Q 2021) May 07
ViewRay, Inc. Reiterates Earnings Guidance for the Year 2022 May 06
ViewRay, Inc., Annual General Meeting, Jun 10, 2022 May 02
ViewRay, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 22
Insider recently bought €88k worth of stock Mar 15
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 26
Viewray, Inc. Provides Revenue Guidance for the Year 2022 Feb 25
ViewRay Announces Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer Feb 16
ViewRay, Inc. to Report Q4, 2021 Results on Feb 24, 2022 Feb 11
Chief Financial Officer recently bought €88k worth of stock Nov 20
Chief Financial Officer recently bought €181k worth of stock Aug 26
Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 2Q 2020) Aug 08 ViewRay, Inc.(NasdaqGM:VRAY) dropped from Russell Microcap Value Index
ViewRay, Inc. Not to Provide Financial Guidance May 08
First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.19 loss in 1Q 2020) May 08
Chief Operating Officer has left the company Apr 02
ViewRay, Inc. Announces the Resignation of Shahriar Matin as Chief Operating Officer, Effective from March 31, 2021 Mar 16
Full year 2020 earnings released: US$0.73 loss per share (vs US$1.18 loss in FY 2019) Mar 05
Revenue beats expectations Mar 05
ViewRay, Inc. to Report Q4, 2020 Results on Mar 04, 2021 Feb 20
Independent Director has left the company Feb 16
ViewRay, Inc. Announces Retirement of D. Keith Grossman from Board of Directors Feb 13
Viewray, Inc. Appoints Phil Spencer to Its Board of Directors Feb 12
Edogawa Hospital in Tokyo Installs Japan's First ViewRay MRIdian Linac Feb 05
The Henry Ford Cancer Institute Installs Its Second Viewray Mridian® Linac Jan 28
An unknown buyer acquired 7.3% stake in ViewRay, Inc. (NasdaqGM:VRAY) from Elekta AB (publ) (OM:EKTA B) for $53.5 million. Jan 22
ViewRay, Inc. has completed a Follow-on Equity Offering in the amount of $50.0035 million. Jan 05
New 90-day high: €4.22 Jan 05
New 90-day high: €3.68 Dec 11
New 90-day high: €3.26 Nov 14
President recently bought €423k worth of stock Nov 14
Universitair Ziekenhuis Brussels Purchases ViewRay's MRIdian Linac Nov 11
Third quarter 2020 earnings released: US$0.19 loss per share Nov 07
Revenue beats expectations Nov 07
ViewRay, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 16
New 90-day high - €3.00 Aug 05
ViewRay, Inc. to Report Q2, 2020 Results on Jul 30, 2020 Jul 17 Shareholder Returns 6L9 DE Medical Equipment DE Market 7D 0% -2.9% -2.6% 1Y -99.4% -8.5% 6.9%
See full shareholder returns
Return vs Market: 6L9 underperformed the German Market which returned 5.9% over the past year.
Price Volatility Is 6L9's price volatile compared to industry and market? 6L9 volatility 6L9 Average Weekly Movement n/a Medical Equipment Industry Average Movement 6.6% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 6L9's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 6L9's volatility change over the past year.
About the Company ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors.
Show more ViewRay, Inc. Fundamentals Summary How do ViewRay's earnings and revenue compare to its market cap? 6L9 fundamental statistics Market cap €17.37k Earnings (TTM ) -€104.59m Revenue (TTM ) €100.27m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 6L9 income statement (TTM ) Revenue US$105.86m Cost of Revenue US$97.34m Gross Profit US$8.52m Other Expenses US$118.94m Earnings -US$110.41m
Last Reported Earnings
Mar 31, 2023
Earnings per share (EPS) -0.60 Gross Margin 8.05% Net Profit Margin -104.30% Debt/Equity Ratio 140.7%
How did 6L9 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/10/27 03:17 End of Day Share Price 2023/08/03 00:00 Earnings 2023/03/31 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources ViewRay, Inc. is covered by 12 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason Bednar Baird Andrew D'Silva B. Riley Securities, Inc. Michael Gorman BTIG
Show 9 more analysts 
